This morning Amylin Pharmaceuticals Inc.(NASDAQ:AMLN) is declining lower by 24.0 percent as the companies diabetes drug failed to beat a competitors drug in a head to head test. The stock price is nearing it’s October 2010 low which was $9.50 a share. This double bottom low price will be some short term support for Amylin stock.
Nicholas Santiago started trading in 1991. In 1997, he became a licensed Series 7 and 63 registered representative. He managed money for a large, affluent private client group. After applying his knowledge to his client base, he decided it was time to begin teaching those interested in learning his methods. He is an expert in Technical Analysis. He has become an accomplished technician in the studies of Elliot Wave, Gann Theory, Dow Theory and Cycle Theory. In 2007, he partnered with Gareth Soloway to form InTheMoneyStocks.Com and realize his dream of educating others about the truth of the markets.
Leave a Reply